36 research outputs found
Planet Hunters. VI: An Independent Characterization of KOI-351 and Several Long Period Planet Candidates from the Kepler Archival Data
We report the discovery of 14 new transiting planet candidates in the Kepler
field from the Planet Hunters citizen science program. None of these candidates
overlapped with Kepler Objects of Interest (KOIs) at the time of submission. We
report the discovery of one more addition to the six planet candidate system
around KOI-351, making it the only seven planet candidate system from Kepler.
Additionally, KOI-351 bears some resemblance to our own solar system, with the
inner five planets ranging from Earth to mini-Neptune radii and the outer
planets being gas giants; however, this system is very compact, with all seven
planet candidates orbiting AU from their host star. A Hill
stability test and an orbital integration of the system shows that the system
is stable. Furthermore, we significantly add to the population of long period
transiting planets; periods range from 124-904 days, eight of them more than
one Earth year long. Seven of these 14 candidates reside in their host star's
habitable zone.Comment: 27 pages, 6 figures, 5 tables, Accepted to AJ (in press) (updated
title from original astro-ph submission
If we implement it, will they come? User resistance in post-acceptance usage behaviour within a business intelligence systems context
High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial.
Information and business performance: a study of information systems and services in high-performing companies
Phase III, randomized, open-label study of triweekly versus biweekly docetaxel (T) as a treatment for advanced hormone-refractory prostate cancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study 1-2003.
Creation of a novel class of potent and selective MutT Homologue 1 (MTH1) inhibitors using fragment-based screening and structure-based drug design
Recent literature has both suggested and questioned MTH1 as a novel cancer target. BAY-707 was just published as a target validation small molecule probe for assessing the effects of pharmacological inhibition of MTH1 on tumor cell survival, both in vitro and in vivo. (1) In this report, we describe the medicinal chemistry program creating BAY-707, where fragment-based methods were used to develop a series of highly potent and selective MTH1 inhibitors. Using structure-based drug design and rational medicinal chemistry approaches, the potency was increased over 10,000 times from the fragment starting point while maintaining high ligand efficiency and drug-like properties